Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0549 • ACR Convergence 2023
Development of Customized Digital Cognitive Assessment Battery: A Pilot Use Case in SLE Patients
Priyanka Srivastava¹ and Liza Rajasekhar², ¹International Institute of Information Technology, Hyderabad, India, ²Nizam's Institute of Medical Sciences, Madhapur, India
Background/Purpose: Reported prevalence of cognitive dysfunction (CD) in SLE varies from 3%-88%1.Variability may be due to use of tools insensitive to population characteristics like literacy,…
Abstract Number: 0566 • ACR Convergence 2023
Characterization of Disease Activity Using a Novel Physiologic Biomarker in Pediatric SLE
Sangeeta Sule, Olivia Lamanna, Kevin Jackson, Sun-Young Ahn, Tineer Ahmed and Julia Finkel, Children's National Hospital, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex inflammatory disease involving many organ systems. To better understand and treat SLE, two phenotypes have been proposed.…
Abstract Number: 0584 • ACR Convergence 2023
Targeting Key Components of SLE Pathogenesis with the Multifaceted Immunomodulatory Properties of Cenerimod, a Selective S1P1 Receptor Modulator
Thomas Hoyler¹, Daniel Strasser¹, Ouali Berkani², Peter Cornelisse¹, Mark Murphy¹ and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, ²IDORSIA, Allschwil, Switzerland
Background/Purpose: In SLE, aberrant lymphocyte activation and autoantibody production result in deposition of immune complexes and contribute to tissue damage. Cenerimod, a highly selective S1P1…
Abstract Number: 0602 • ACR Convergence 2023
Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus
Elizabeth Repash, Tiffany Blair, Amanda Enstrom, Lawrence Evans, Susan Debrot, Katherine Lewis, Armand Bankhead, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA
Background/Purpose: CD28 and inducible T cell costimulator (ICOS) play nonredundant roles in T cell activation and inhibiting these pathways can ameliorate an (auto)immune response. Systemic…
Abstract Number: 0786 • ACR Convergence 2023
A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort
Anna Arar, Diane L. Kamen, Paul Nietert and Melissa Cunningham, Medical University of South Carolina, Charleston, SC
Background/Purpose: Manifestations of systemic lupus erythematous (SLE) vary in severity and presentation; lupus nephritis (LN) affects up to half of SLE patients and confers a…
Abstract Number: 0895 • ACR Convergence 2023
Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus
Chaim Putterman¹, Elise Mike² and Sayra Garcia¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Johns Hopkins, Bronx, NY
Background/Purpose: One central mechanism believed to contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is temporary disruption of the blood brain barrier (BBB).…
Abstract Number: 0914 • ACR Convergence 2023
Transcription Factor RFX1 Promotes M1 Macrophage Polarization in Systemic Lupus Erythematosus via Regulating APOBEC3A
shuang Yang¹, Pei Du¹, Sujie Jia² and Ming Zhao², ¹Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital of Central South University, Changsha, China, ²Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China
Background/Purpose: Aberrant macrophage polarization is generally present in autoimmune diseases. Overwhelming M1 macrophage induces the continuous progression of inflammation, which is one of the vital…
Abstract Number: 1009 • ACR Convergence 2023
More Implementation Strategies Are Not Associated with Better Implementation Outcomes: Implementing the Lupus Patient Decision Aid
larry hearld, Jasvinder Singh and Mark Beasley, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To assess the association of the number of implementation strategies for a patient lupus decision aid (DA) with perceived implementation outcomes, and the moderating…
Abstract Number: 1237 • ACR Convergence 2023
The Associations Between Depressive Symptoms and Executive Function and Academic Outcomes in Children with SLE
Hannah Bradfield¹, Paola Sparagana², Elizabeth Sloan¹, Chanhee Jo³, Tracey Wright¹ and Sheryl Frierson², ¹UT Southwestern, Dallas, TX, ²Scottish Rite for Children, Dallas, TX, ³Texas Scottish Rite Hospital, Dallas, TX
Background/Purpose: Children with juvenile-onset SLE (jSLE) have high rates of depression.1-2 Adolescents with depression, but without a chronic illness, have lower academic engagement, efficacy, and…
Abstract Number: 1364 • ACR Convergence 2023
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴, Rebecca Jacobson¹ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE). Methods: We used a longitudinal cohort that…
Abstract Number: 1458 • ACR Convergence 2023
Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity
Kittikorn Wangriatisak¹, Francesca Faustini², Charlotte de Vries³, Ravi Kumar Sharma⁴, Caroline Grönwall⁵, Prapaporn Pisitkun⁶, Patchanee Chootong⁷, Vivianne Malmström⁵ and Iva Gunnarsson⁸, ¹Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Thailand ; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bankok, Thailand, ⁷Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, ⁸Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Sweden, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), which is characterized by abnormal B-cell activation and their…
Abstract Number: 1474 • ACR Convergence 2023
Associations and Outcomes of Critical Peripheral Ischemia in Systemic Lupus Erythematosus (SLE): Data from Indian SLE Inception Cohort for Research (INSPIRE)
Vineeta Shobha¹, Liza Rajasekhar², Sandra Manuel³, Nayana V³, Ranjan Gupta⁴, Bidyut Das⁵, Parasar Ghosh⁶, Chengappa Kavadichanda⁷, Ashish J Mathew⁸, Manish Rathi⁹, Avinash Jain¹⁰, Sumithra Selvam³ and Amita Aggarwal¹¹, ¹St. John's National Academy of Health Science, Bangalore, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³St. John's Research Institute, Bangalore, India, ⁴All India Institute of Medical Sciences, New Delhi, India, ⁵SCB medical college, Cuttack, India, ⁶Govt of West Bengal, Kolkata, India, ⁷Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁸Christian Medical College, Vellore, India, ⁹Postgraduate Institute of Medical education and Research, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India, ¹¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India
Background/Purpose: Among the cutaneous manifestations of SLE, critical peripheral ischemia (CPI) including digital infarcts and gangrene are considered rare, gangrene occurring only in about 0.2%…
Abstract Number: 1492 • ACR Convergence 2023
Pre-treatment Differentially Expressed Metagenes Characterize Systemic Lupus Patients Who Subsequently Achieve Clinical Response to Belimumab
Miles Smith¹, Kevin Thomas¹, Nicolas Dominguez¹, Susan Macwana¹, Wade DeJager¹, Stan Kamp¹, Carla Guthridge¹, Bridget Parrish¹, Cristina Arriens², Judith James¹, Joan Merrill¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK
Background/Purpose: Belimumab, which targets the B Cell activator and survival factor BLyS, is an approved treatment for systemic lupus (SLE) and has demonstrated efficacy in…
Abstract Number: 1510 • ACR Convergence 2023
Efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in Women with Systemic Lupus Erythematosus (SLE) Receiving Cyclophosphamide (CYC)
Jun Chu¹, Dania Abid², Zerai Manna¹, Subrata Paul³, Isabel Ochoa³, Yalan Wu³, Sonia Goyal⁴, Syed Ali Abbas Naqvi⁵, Lubna Hooda³ and Sarfaraz Hasni³, ¹Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ²Idaho College of Osteopathic Medicine, Meridian, ID, ³National Institutes of Health, Bethesda, MD, ⁴George Washington University, Washington, DC, ⁵Jewish Hospital of Cincinnati, Cincinnati, OH
Background/Purpose: SLE patients with life-threatening lupus manifestations are often treated with cyclophosphamide (CYC), which has known cytotoxic effects on ovarian reserve. Co-administration of Gonadotropin-releasing hormone…
Abstract Number: 1616 • ACR Convergence 2023
Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies
Joshua Skydel¹, Reshma Ramachandran², Sakinah Suttiratana², Joseph Ross², Joshua Wallach³ and Christopher Burns⁴, ¹Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Yale University, New Haven, CT, ³Emory University, Atlanta, GA, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].